ArticleWorld journal of surgical oncology2026
Coagulation factor V as a novel regulator of tumor immunity in melanoma.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecent advances in melanoma treatment, including targeted therapies and immunotherapies, have improved patient outcomes. The discovery of molecular targets is crucial, enabling more precise treatment strategies that address specific genetic mutations. Our study delves into the multifunctional role of coagulation factor Coagulation Factor V (F5) in melanoma.
methodsThe melanoma data about gene expression, clinical information, prognosis, and immune infiltration were obtained from TCGA database. The A2058 cell were used to examine the effects of F5 in the behavior of tumor cells in vitro.
resultsOur results revealed that F5 expression levels in melanoma patients are significantly correlated with prognosis, with lower expression levels associated with poorer outcomes. Single-cell transcriptomic analysis further revealed a strong association between F5 expression and diverse immune cell populations and chemokines. In addition, overexpression of F5 in the melanoma cell line A2058 significantly inhibited cell migration, proliferation, and colony formation capacity, while upregulating the expression of multiple immune chemokines.
conclusionsThese findings go beyond the traditional view of F5 as a coagulation factor and reveal its importance in immunomodulation and tumor biology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.